Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B. Haas, Judith Manola, Robert G. Uzzo, Keith T. Flaherty, Christopher G. Wood, Christopher Kane, Michael Jewett, Janice P. Dutcher, Michael B. Atkins, Michael Pins, George Wilding, David Cella, Lynne Wagner, Surena Matin, Timothy M. Kuzel, Wade J. Sexton, Yu Ning Wong, Toni K. Choueiri, Roberto Pili, Igor PuzanovManish Kohli, Walter Stadler, Michael Carducci, Robert Coomes, Robert S. Dipaola
Dive into the research topics of 'Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial'. Together they form a unique fingerprint.